Skip to main content
. 2024 Jun 15;21(4):e00384. doi: 10.1016/j.neurot.2024.e00384

Fig. 4.

Fig. 4

Dose-response of VU846 auditory-event related features. A. Normalized AEP peak amplitudes (normalized to individual animal baseline values prior to injection: A1-P1; A2-N1; A3-P2) after treatment with vehicle or doses of VU846 indicated along the X-axis. B. VU846 dose-response effects on P2 rising (B1) and decay (B2) slopes. C. Change in ESRP after VU846 injection at various doses compared to vehicle injection in low frequency bands (C1, 0–12 ​Hz) and high frequency bands (C2, 12–100Hz). D. Change in ITPC after VU846 injection at various doses compared to vehicle injection in low frequency bands (C1, 0–12 ​Hz) and high frequency bands (C2, 12–100Hz). ∗p ​< ​0.05, ∗∗p ​< ​0.01, within genotype ANOVA with post-hoc Tukey pairwise comparison between VU846 dose and vehicle.